Established in 1999, Senzime develops and markets precision-based monitoring systems that improve outcomes, reduce costs, and advance perioperative patient safety. The company has a strategic license and connectivity agreement with Masimo to develop and market the TetraGraph Smart Cable Module that connects directly to their Root monitoring system and digital hubs for hospital integration. Senzime operates in Sweden, Germany and the USA.
Cyborg Score Rationale
Early-stage medical device company with strong market positioning in perioperative monitoring and FDA/CE clearances. Revenue growth evident (~39% YoY) but small revenue base (~$7.75M TTM) and negative EPS (-$0.09) indicate commercialization challenges. Strategic partnerships (Masimo, Fukuda Denshi) and geographic expansion provide growth avenues.
Top Insights
Portfolio focused on two core platforms (TetraGraph for neuromuscular monitoring, ExSpiron for respiratory monitoring) addressing high-incidence postoperative complications in 100M+ patient markets
Strategic partnerships with major medical device companies (Masimo, Fukuda Denshi, Philips) accelerate market penetration and reduce commercialization burden
Recent US market expansion through hospital system wins and regulatory approvals in Japan/South Korea indicate successful international scaling trajectory
Small-cap structure ($117M market cap) with institutional backing creates risk/reward profile typical of early-stage medtech with significant upside if commercialization accelerates
Named Competitors
Patient Monitoring Systems — Broad perioperative monitoring portfolio with integrated platform approach
Neuromuscular Monitoring — Non-invasive monitoring partner with distribution and integration advantages